(BAYN) Bayer NA - Ratings and Ratios
Pharmaceuticals, Consumer Health, Crop Protection, Seeds, Digital Agriculture
BAYN EPS (Earnings per Share)
BAYN Revenue
Description: BAYN Bayer NA
Bayer Aktiengesellschaft (XETRA:BAYN) is a global life-science conglomerate organized into three core segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division focuses on prescription medicines for cardiology, womens health, oncology, hematology, and ophthalmology, and also supplies diagnostic imaging agents and emerging cell- and gene-therapy platforms.
The Consumer Health unit sells over-the-counter (OTC) products ranging from pain relievers and cardiovascular-risk prevention items to nutraceuticals, skincare, allergy, and cold-and-cough remedies. Distribution channels include pharmacies, supermarkets, online retailers, and direct-to-consumer platforms.
Crop Science provides chemical and biological crop-protection chemicals, seed traits, digital farming solutions, and related services. The segment also handles seed breeding, propagation, and processing, and it markets directly to farmers as well as through agricultural distributors.
Key recent metrics (FY 2023) show total revenue of €48.3 billion, with Pharmaceuticals contributing roughly 45 % of sales, Consumer Health about 12 %, and Crop Science the remaining 43 %. R&D expenditure stayed near €6 billion, reflecting continued investment in oncology pipelines (e.g., Xofigo) and gene-therapy platforms. EBIT margin hovered around 12 %, pressured by legacy litigation costs and volatile commodity prices affecting Crop Science.
Sector-level drivers that materially affect Bayer’s outlook include: (1) an aging global population driving higher demand for chronic-disease drugs; (2) tightening environmental regulations and a shift toward sustainable agriculture, which boost demand for biological crop-protection products and digital farming tools; and (3) macro-economic exposure to commodity price cycles that can erode Crop Science margins during periods of high input costs.
Given these dynamics, analysts should monitor the rollout speed of Bayer’s next-generation oncology candidates and the adoption rate of its digital agronomy platform, as both are high-impact levers for future earnings growth.
For a deeper, data-driven assessment of Bayer’s valuation relative to its peers, you might find ValueRay’s interactive analytics useful.
BAYN Stock Overview
| Market Cap in USD | 32,317m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
BAYN Stock Ratings
| Growth Rating | -14.1% |
| Fundamental | 49.1% |
| Dividend Rating | 1.0% |
| Return 12m vs S&P 500 | -12.0% |
| Analyst Rating | - |
BAYN Dividends
| Dividend Yield 12m | 0.41% |
| Yield on Cost 5y | 0.28% |
| Annual Growth 5y | -55.48% |
| Payout Consistency | 87.6% |
| Payout Ratio | 2.2% |
BAYN Growth Ratios
| Growth Correlation 3m | -8.5% |
| Growth Correlation 12m | 80.7% |
| Growth Correlation 5y | -62.7% |
| CAGR 5y | -17.63% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.26 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.44 |
| Sharpe Ratio 12m | 1.12 |
| Alpha | -13.87 |
| Beta | 1.003 |
| Volatility | 30.96% |
| Current Volume | 3790k |
| Average Volume 20d | 1849k |
| Stop Loss | 25.9 (-3.4%) |
| Signal | -0.34 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (-3.42b TTM) > 0 and > 6% of Revenue (6% = 2.77b TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 0.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 8.60% (prev 18.22%; Δ -9.62pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 7.15b > Net Income -3.42b (YES >=105%, WARN >=100%) |
| Net Debt (-4.56b) to EBITDA (6.55b) ratio: -0.70 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (982.4m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 54.95% (prev 58.07%; Δ -3.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 41.03% (prev 39.31%; Δ 1.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.83 (EBITDA TTM 6.55b / Interest Expense TTM 1.71b) >= 6 (WARN >= 3) |
Altman Z'' 0.64
| (A) 0.04 = (Total Current Assets 33.75b - Total Current Liabilities 29.78b) / Total Assets 105.24b |
| (B) 0.09 = Retained Earnings (Balance) 9.87b / Total Assets 105.24b |
| (C) -0.01 = EBIT TTM -1.42b / Avg Total Assets 112.55b |
| (D) 0.16 = Book Value of Equity 12.11b / Total Liabilities 74.74b |
| Total Rating: 0.64 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 49.07
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 7.58% = 3.79 |
| 3. FCF Margin 9.95% = 2.49 |
| 4. Debt/Equity 1.27 = 1.75 |
| 5. Debt/Ebitda -0.70 = 2.50 |
| 6. ROIC - WACC (= -5.94)% = -7.43 |
| 7. RoE -10.91% = -1.82 |
| 8. Rev. Trend -9.63% = -0.72 |
| 9. EPS Trend -9.65% = -0.48 |
What is the price of BAYN shares?
Over the past week, the price has changed by -4.16%, over one month by -2.06%, over three months by -4.13% and over the past year by +1.68%.
Is Bayer NA a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BAYN is around 22.85 EUR . This means that BAYN is currently overvalued and has a potential downside of -14.8%.
Is BAYN a buy, sell or hold?
What are the forecasts/targets for the BAYN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.5 | 6.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 24.5 | -8.5% |
BAYN Fundamental Data Overview
Market Cap EUR = 27.70b (27.70b EUR * 1.0 EUR.EUR)
P/E Forward = 5.5218
P/S = 0.6
P/B = 0.9333
P/EG = 4.7193
Beta = 1.003
Revenue TTM = 46.17b EUR
EBIT TTM = -1.42b EUR
EBITDA TTM = 6.55b EUR
Long Term Debt = 34.55b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 6.72b EUR (from shortTermDebt, last quarter)
Debt = 38.43b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -4.56b EUR (from netDebt column, last quarter)
Enterprise Value = 60.64b EUR (27.70b + Debt 38.43b - CCE 5.50b)
Interest Coverage Ratio = -0.83 (Ebit TTM -1.42b / Interest Expense TTM 1.71b)
FCF Yield = 7.58% (FCF TTM 4.59b / Enterprise Value 60.64b)
FCF Margin = 9.95% (FCF TTM 4.59b / Revenue TTM 46.17b)
Net Margin = -7.40% (Net Income TTM -3.42b / Revenue TTM 46.17b)
Gross Margin = 54.95% ((Revenue TTM 46.17b - Cost of Revenue TTM 20.80b) / Revenue TTM)
Gross Margin QoQ = 59.36% (prev 59.06%)
Tobins Q-Ratio = 0.58 (Enterprise Value 60.64b / Total Assets 105.24b)
Interest Expense / Debt = 1.29% (Interest Expense 495.0m / Debt 38.43b)
Taxrate = 55.40% (-236.0m / -426.0m)
NOPAT = -634.7m (EBIT -1.42b * (1 - 55.40%)) [loss with tax shield]
Current Ratio = 1.13 (Total Current Assets 33.75b / Total Current Liabilities 29.78b)
Debt / Equity = 1.27 (Debt 38.43b / totalStockholderEquity, last quarter 30.37b)
Debt / EBITDA = -0.70 (Net Debt -4.56b / EBITDA 6.55b)
Debt / FCF = -0.99 (Net Debt -4.56b / FCF TTM 4.59b)
Total Stockholder Equity = 31.32b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.25% (Net Income -3.42b / Total Assets 105.24b)
RoE = -10.91% (Net Income TTM -3.42b / Total Stockholder Equity 31.32b)
RoCE = -2.16% (EBIT -1.42b / Capital Employed (Equity 31.32b + L.T.Debt 34.55b))
RoIC = -1.54% (negative operating profit) (NOPAT -634.7m / Invested Capital 41.18b)
WACC = 4.40% (E(27.70b)/V(66.13b) * Re(9.71%) + D(38.43b)/V(66.13b) * Rd(1.29%) * (1-Tc(0.55)))
Discount Rate = 9.71% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -0.00%
[DCF Debug] Terminal Value 67.06% ; FCFE base≈4.68b ; Y1≈3.58b ; Y5≈2.23b
Fair Price DCF = 32.66 (DCF Value 32.09b / Shares Outstanding 982.4m; 5y FCF grow -27.83% → 3.0% )
EPS Correlation: -9.65 | EPS CAGR: 3.13% | SUE: 1.55 | # QB: 1
Revenue Correlation: -9.63 | Revenue CAGR: -1.77% | SUE: 0.18 | # QB: 0